Hurthle Cell Thyroid Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Hurthle Cell Thyroid Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingNot Applicable

NCT00001160

Studies on Tumors of the Thyroid

Participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. The main purpose of this study is to furthe…

United States2,500 participantsStarted 1977-06-01

Treatment: 68-Gallium Dotatate

All recent trials (15 shown)

Not Yet RecruitingPhase 1/2

NCT06991738

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid…

Background: Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targ…

United States18 participantsStarted 2026-05-13

Treatment: 68Ga-DOTA-TATE PET Scan, Amino acid infusions

Active — Not RecruitingPhase 2/3

NCT01398085

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.

United Kingdom504 participantsStarted 2012-06-26

Treatment: I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation

Hurthle Cell Thyroid Cancer

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Studies on Tumors of the Thyroid

All recent trials (15 shown)

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid…

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Studies on Tumors of the Thyroid

All recent trials (15 shown)

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid…

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle…

Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Io…

A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer